The results of retrospective analyses suggest that related donors (RDs) are at greater risk of donation-associated adverse events, including death, compared with unrelated donors (UDs). 1, 2 This occurs in part because RDs are frequently accepted as hematopoietic cell (HPC) donors with morbidities for which an UD would be deferred. 3, 4 In the UK, the Human Tissue Authority (HTA) is responsible for implementation of legislation regarding collection, storage and use of tissue from living donors, the cornerstone of which is informed consent. 5 Joint accreditation of ISCT and EBMT (JACIE) accreditation, required to ensure reimbursement, necessitates compliance with standards aimed at protecting the health and interests of relatives donating, and preventing disease transmission to transplant recipients. 6 However, unlike UD practice where World Marrow Donor Association (WMDA) Standards 7 define best practice at each stage of the donor care pathway, neither Foundation for the Accreditation of Cellular Therapy (FACT)-JACIE Standards nor the HTA Code of Practice, do so. Although both mandate donor virology tests to prevent disease transmission to recipients, standards regarding RD health are more generic, for example, requiring the existence of policies rather than defining their content. International organizations including the Worldwide Network for Blood and Marrow Transplantation (WBMT) 8 and the WMDA 9 have produced consensus recommendations that are more definitive, but we do not know how extensively these have been adopted by transplant centers.
This study aimed to investigate current UK related donor (RD) practice by examining compliance with FACT-JACIE Standards and international consensus recommendations and investigating how assessment of donor medical suitability is conducted across transplant centers. We also sought to determine the views of UK RD care physicians regarding current care pathways and attitudes to guideline development.
A 47-item survey developed to address the study objectives (see Supplementary materials), was administered as an internet-based questionnaire (surveymonkey.com) from April to July 2014. Directors of the 28 UK transplant programs performing adult allogeneic HCTs and one adult apheresis unit managing RDs were contacted via the British Society for Blood and Marrow Transplantation (BSBMT). The invitation to participate included a request to forward the survey to the consultant responsible for RD care. Non-responders received three further email reminders, and, when duplicate responses were received the most complete one was used for analysis. Participants were able to skip questions they were unable to answer. The study was approved by the BSBMT Clinical Trials Committee.
Excluding duplicates, 22 centers (76%) responded. Response rate did not vary significantly among geographical regions or by center volume, but all eight highest volume transplant centers (performing 460 allografts per year) responded. Nineteen of 22 responding centers (86%) were JACIE accredited, and one further center had undergone first inspection but had not yet received accreditation.
As shown in Table 1A , we found near universal compliance with the majority of FACT-JACIE Standards, including the existence of a written policy for RD care in 96% of centers, and the use of defined medical suitability criteria to assess RDs in 86% of centers. Accreditation status influenced the presence of a defined policy for RD care; of the two centers not yet JACIE-inspected or accredited, one center did not have a policy for RD care, while all other 19 centers with accreditation had an RD care policy (P = 0.005). All respondents confirmed compliance with the requirement to provide RDs with information about donation before HLA typing, which included written information in 86% of centers.
Respondents stated that RDs are consented by transplant physicians in 50% of centers, by a physician from a separate team in 41% of centers and by a physician from another organization in 9% of centers. Only one respondent indicated that their center was unable to meet the FACT-JACIE recommendation to separate donor and recipient care, by stating that the same physician would be simultaneously responsible for the care of the recipient.
We examined aspects of care that have not been addressed in FACT-JACIE Standards, but where published consensus criteria have aimed to harmonize practice. Consistency was found in some areas including that 96% of centers stated compliance with the recommendation to verify donor willingness to donate before performing HLA typing, 10 and 82% adherence to the recommendation that donors should be informed of their HLA matching status before the recipient. 9 Responses regarding compliance in other areas were varied, notably including that 36% respondents stated that no health assessment of potential donors is performed before HLA-typing.
Centers also differed in their approach to donor follow-up; while 96% of centers perform short-term follow-up (1-4 weeks post donation), only 23% continue follow-up to 5 years and 14% to 10 years. Donor follow-up is undertaken using a variety of methods, most commonly via telephone, and only 14% of centers used written donor follow-up questionnaires, all of which were centers where one of the transplant physicians is concurrently employed by a UK UD registry. 23% of centers report data to EBMT using donor outcome forms, a further 36% were familiar with these forms but these were not used in their center, and the remaining 36% of respondents were unfamiliar with this option for reporting donor data.
As shown in Table 1B , we found diversity among centers regarding the investigations routinely performed during donor evaluation, and the health conditions or parameters with which donors would be considered suitable. Variation in policies concerning the donation procedure was also demonstrated (Table 1B) . Of note, this included that five centers (24%) had used off-label plerixafor to mobilize related donors.
Fifty seven per cent of physicians described UK RD care as satisfactory. The most commonly stated reasons for considering care to be unsatisfactory were lack of standardized guidelines and inadequate donor follow-up. Sixty seven per cent felt that national RD suitability criteria would improve donor health and 81% responded that guidelines for whole donation process would improve care. As shown in Figure 1 , mixed opinions were expressed regarding the optimal model for RD care in the UK, but, notably, only 27% of respondents thought that RD care should be performed by a separate organization to the recipient's transplant center.
The results of this study provide an in-depth analysis of RD care which, with a response rate of 475%, we believe to be representative of UK practice. We are able to show near universal consistency in RD care where clear FACT-JACIE Standards exist, including the presence of policies for RD care, provision of information before HLA typing, and taking measures to prevent the same physician being simultaneously responsible for donor and recipient care. However, consensus recommendations around RD care have not been widely adopted, and we show distinct differences among transplant centers in both the criteria and investigations employed during donor evaluation. Furthermore, our results demonstrate that this leads to inconsistent approaches to RDs with medical issues, where RDs who would be accepted by some centers would be deferred by others.
Discrepancies between centers in the approach to acceptance of RDs is not surprising given the lack of national RD suitability criteria. Although clear medical criteria are available for UDs (refs), these cannot be directly applied to RDs. Although some experts would argue that RDs should not be permitted to undergo more risk than UDs, many others feel that the risk/benefit ratio is different for RDs due to the potential psychological benefit from a Abbreviations: BM = bone marrow; BMI = body mass index; BP = blood pressure; CXR = chest x-ray; ECG = electrocardiography; G-CSF = granulocytecolony stimulating factor; HPC = hematopoietic cell; RD = related donor. successful transplant outcome. 10 It is generally accepted that it is wrong to expose any donor to a known substantial health risk, but there are gray areas, where the risks are theoretical or inadequately defined. In the UD setting these gray areas rightly lead to deferral, but in the RD setting flexibility may be appropriate, for example using a protocol exception system to gain specific consent regarding a potential increased risk.
The most notable areas where consensus guidelines have not been adopted are assessment of RD health before HLA typing and RD follow-up. Although donors are counseled before HLA typing in all centers, and willingness to proceed is verified in all but one center, 36% of centers do not undertake a health assessment at this point. Assessment of potential RD health before HLA typing is necessary both to prevent delays to the transplant recipient by reducing deferrals at the point of donor medical evaluation and by reducing potential distress or guilt to the RD by being canceled after they are known to be HLA-matched. If this is not possible, it is important that centers make RDs and recipients aware that being matched does not guarantee the donor suitability. Similarly, there is a strong rationale for long-term donor follow-up to ensure that we are not exposing donors to long-term health complications, particularly since some centers are using off-label plerixafor; however, this is only performed in three centers. We suspect that logistical issues are responsible for the failure to develop follow-up systems in UK transplant centers, however, these can potentially be conducted with minimal resource implications if standardized questionnaires are used to collect a minimum data set. Finally, we show enthusiasm for development of RD guidelines and suitability criteria, which we hope will promote standardized RD care in the UK.
